Tenax Total Assets from 2010 to 2024

TENX Stock

USD 5.36 0.03 0.56%

Tenax Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1996-09-30

Previous Quarter

10.6 M

Current Value

99.8 M

Quarterly Volatility

22.3 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 K, Other Operating Expenses of 8.4 M or Research Development of 3.6 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 0.71. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.

Check out the analysis of Tenax Therapeutics Correlation against competitors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Latest Tenax Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Tenax Therapeutics over the last few years. Total assets refers to the total amount of Tenax Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tenax Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Tenax Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tenax Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 11.68 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Tenax Total Assets Regression Statistics

	Arithmetic Mean	25,608,821
	Geometric Mean	10,449,735
	Coefficient Of Variation	138.88
	Mean Deviation	27,128,248
	Median	9,890,701
	Standard Deviation	35,565,200
	Sample Variance	1264.9T
	Range	93M
	R-Value	(0.29)
	Mean Square Error	1250T
	R-Squared	0.08
	Significance	0.30
	Slope	(2,281,848)
	Total Sum of Squares	17708.4T

Tenax Total Assets History

	2024	15.5 M
	2023	11.7 M
	2022	3.4 M
	2021	6 M
	2020	6.9 M
	2019	6.4 M
	2018	13.3 M

Other Fundumenentals of Tenax Therapeutics

Intangibles To Total Assets

Tenax Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt	Current Deferred Revenue	Net Tangible Assets	Short Term Investments	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		1.0	-0.99	0.27	-0.14	0.89	1.0	0.26	-0.19	-0.39	-0.31	-0.15	0.94	0.66	0.15	-0.33	0.32	0.21	-0.21	0.12
Total Stockholder Equity	1.0		-1.0	0.25	-0.14	0.87	1.0	0.27	-0.18	-0.4	-0.33	-0.19	0.94	0.67	0.18	-0.33	0.31	0.21	-0.2	0.12
Net Debt	-0.99	-1.0		-0.22	0.1	-0.85	-1.0	-0.28	0.19	0.39	0.34	0.2	-0.93	-0.63	-0.21	0.31	-0.29	-0.22	0.2	-0.1
Retained Earnings	0.27	0.25	-0.22		-0.53	0.39	0.23	-0.27	0.6	0.27	0.45	0.51	0.17	0.2	-0.86	-0.26	0.54	0.36	-0.33	0.42
Accounts Payable	-0.14	-0.14	0.1	-0.53		-0.11	-0.11	0.05	-0.31	-0.05	-0.19	-0.18	-0.11	-0.41	0.4	0.21	-0.23	-0.09	-0.37	-0.77
Total Liab	0.89	0.87	-0.85	0.39	-0.11		0.87	0.13	-0.27	-0.29	-0.02	0.22	0.8	0.55	-0.09	-0.27	0.35	0.2	-0.26	0.15
Total Current Assets	1.0	1.0	-1.0	0.23	-0.11	0.87		0.27	-0.21	-0.41	-0.34	-0.18	0.94	0.66	0.2	-0.33	0.32	0.23	-0.22	0.11
Short Term Debt	0.26	0.27	-0.28	-0.27	0.05	0.13	0.27		0.04	0.27	-0.36	-0.38	0.23	0.06	0.4	0.45	-0.33	-0.35	0.49	-0.2
Common Stock	-0.19	-0.18	0.19	0.6	-0.31	-0.27	-0.21	0.04		0.63	0.06	-0.09	-0.23	-0.16	-0.52	0.09	0.15	0.08	-0.07	0.11
Property Plant Equipment	-0.39	-0.4	0.39	0.27	-0.05	-0.29	-0.41	0.27	0.63		0.31	0.25	-0.45	-0.52	-0.45	0.78	-0.18	-0.23	0.29	-0.13
Long Term Debt	-0.31	-0.33	0.34	0.45	-0.19	-0.02	-0.34	-0.36	0.06	0.31		0.9	-0.42	-0.29	-0.73	0.16	0.19	0.11	-0.1	0.13
Current Deferred Revenue	-0.15	-0.19	0.2	0.51	-0.18	0.22	-0.18	-0.38	-0.09	0.25	0.9		-0.27	-0.17	-0.75	0.1	0.26	0.15	-0.14	0.17
Net Tangible Assets	0.94	0.94	-0.93	0.17	-0.11	0.8	0.94	0.23	-0.23	-0.45	-0.42	-0.27		0.53	0.25	-0.32	0.32	0.23	-0.15	0.19
Short Term Investments	0.66	0.67	-0.63	0.2	-0.41	0.55	0.66	0.06	-0.16	-0.52	-0.29	-0.17	0.53		0.12	-0.57	0.31	0.19	-0.18	0.22
Capital Surpluse	0.15	0.18	-0.21	-0.86	0.4	-0.09	0.2	0.4	-0.52	-0.45	-0.73	-0.75	0.25	0.12		0.02	-0.35	-0.19	0.21	-0.24
Short Long Term Debt	-0.33	-0.33	0.31	-0.26	0.21	-0.27	-0.33	0.45	0.09	0.78	0.16	0.1	-0.32	-0.57	0.02		-0.45	-0.43	0.55	-0.26
Net Invested Capital	0.32	0.31	-0.29	0.54	-0.23	0.35	0.32	-0.33	0.15	-0.18	0.19	0.26	0.32	0.31	-0.35	-0.45		0.96	-0.64	0.17
Net Working Capital	0.21	0.21	-0.22	0.36	-0.09	0.2	0.23	-0.35	0.08	-0.23	0.11	0.15	0.23	0.19	-0.19	-0.43	0.96		-0.65	0.08
Capital Stock	-0.21	-0.2	0.2	-0.33	-0.37	-0.26	-0.22	0.49	-0.07	0.29	-0.1	-0.14	-0.15	-0.18	0.21	0.55	-0.64	-0.65		0.33
Long Term Debt Total	0.12	0.12	-0.1	0.42	-0.77	0.15	0.11	-0.2	0.11	-0.13	0.13	0.17	0.19	0.22	-0.24	-0.26	0.17	0.08	0.33

Click cells to compare fundamentals

About Tenax Therapeutics Financial Statements

Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	11.7 M	15.5 M
Intangibles To Total Assets	0.41	0.43

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC